Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1080/10428190802510315 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Clinical outcomes and adverse events of Hedgehog pathway inhibitors for advanced basal cell carcinoma patients: A systematic review and meta-analysis.
Heliyon
January 2025
Division of Ambulatory Medicine, Department of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.
Background: Basal cell carcinoma (BCC) is the most common form of skin cancer and poses treatment challenges in advanced stages. Treatment options include surgery, radiotherapy, and systemic therapies, but tumor location and prior interventions can limit these methods. Hedgehog pathway inhibitors (HPIs) are used for patients unsuitable for conventional treatments.
View Article and Find Full Text PDFClinicopathologic and Molecular Characterization of Basal Cell Carcinoma Arising at Sun-protected Sites.
Am J Surg Pathol
January 2025
Department of Pathology, Brigham and Women's Hospital.
Basal cell carcinomas (BCC) are driven primarily by cumulative ultraviolet (UV) radiation exposure resulting in activation of the Hedgehog (Hh) signaling pathway, often as a result of UV-mediated Patched-1 (PTCH1) gene inactivation. Accordingly, BCCs most commonly arise at sun-exposed sites such as the head and neck. Very rarely, BCCs can arise at sun-protected sites such as the genital skin and perianal area.
View Article and Find Full Text PDFCASE (CemiplimAb-rwlc Survivorship and Epidemiology): a study in advanced basal cell carcinoma.
Future Oncol
January 2025
Department of Cutaneous Oncology, Moffitt Cancer Center, Tampa, FL, USA.
Patients diagnosed with metastatic basal cell carcinoma (BCC) have a poor prognosis. The current standard of care for adults with locally advanced or metastatic BCC who are not candidates for surgery or radiation therapy is treatment with hedgehog pathway inhibitors (HHIs). For patients who progress while on this therapy, further treatment options are limited.
View Article and Find Full Text PDFTherapeutic Approaches for Advanced Basal Cell Carcinoma: A Comprehensive Review.
Cancers (Basel)
December 2024
Department of Dermatology and Allergology, Paracelsus Medical University, Muellner Hauptstraße 48, 5020 Salzburg, Austria.
Basal cell carcinoma (BCC) accounts for 80% of skin cancer cases. Although mostly curable by simple excision, the treatment of advanced disease can be challenging, as curative surgery or radiotherapy may not always be feasible. The scope of this review is to summarize current knowledge on molecular mechanisms in BCC pathogenesis, to elaborate on the definition of advanced/difficult-to-treat BCC, and to outline systemic treatment options.
View Article and Find Full Text PDFWnt Signaling Pathway in Tumor Biology.
Genes (Basel)
December 2024
Department of Hematology, Ion Chiricuta Oncology Institute, 400015 Cluj Napoca, Romania.
Relapse and metastasis are the major challenges that stand in the way of cancer healing and survival, mainly attributed to cancer stem cells (CSCs). Their capabilities of self-renewal and tumorigenic potential leads to treatment resistance development. CSCs function through signaling pathways such as the Wnt/β-catenin cascade.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!